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Background: The actin-bundling protein Fascin (FSCN1) is a tumor marker that is highly expressed in numerous
types of cancer including lymphomas and is important for migration and metastasis of tumor cells. Fascin has also
been detected in B lymphocytes that are freshly-infected with Epstein-Barr virus (EBV), however, both the inducers
and the mechanisms of Fascin upregulation are still unclear.
Results: Here we show that the EBV-encoded oncoprotein latent membrane protein 1 (LMP1), a potent regulator
of cellular signaling and transformation, is sufficient to induce both Fascin mRNA and protein in lymphocytes. Fascin
expression is mainly regulated by LMP1 via the C-terminal activation region 2 (CTAR2). Block of canonical NF-κB
signaling using a chemical inhibitor of IκB kinase β (IKKβ) or cotransfection of a dominant-negative inhibitor of IκBα
(NFKBIA) reduced not only expression of p100, a classical target of the canonical NF-κB-pathway, but also
LMP1-induced Fascin expression. Furthermore, chemical inhibition of IKKβ reduced both Fascin mRNA and protein
levels in EBV-transformed lymphoblastoid cell lines, indicating that canonical NF-κB signaling is required for
LMP1-mediated regulation of Fascin both in transfected and transformed lymphocytes. Beyond that, chemical inhibition
of IKKβ significantly reduced invasive migration of EBV-transformed lymphoblastoid cells through extracellular matrix.
Transient transfection experiments revealed that Fascin contributed to LMP1-mediated enhancement of invasive
migration through extracellular matrix. While LMP1 enhanced the number of invaded cells, functional knockdown of
Fascin by two different small hairpin RNAs resulted in significant reduction of invaded, non-attached cells.
Conclusions: Thus, our data show that LMP1-mediated upregulation of Fascin depends on NF-κB and both NF-κB and
Fascin contribute to invasive migration of LMP1-expressing lymphocytes.
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The DNA virus Epstein-Barr virus (EBV), also termed
Human herpesvirus 4 (HHV-4), infects both B lymphoid
cells and epithelial cells. EBV infections are associated
with cancer as EBV DNA is detected in nearly all cases
of endemic Burkitt lymphoma (BL), nasopharyngeal car-
cinoma (NPC) and, frequently, in Hodgkin lymphomas* Correspondence: andrea.kress@viro.med.uni-erlangen.de
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unless otherwise stated.(HL) [1]. After an initial lytic phase of EBV infection, a
life-long latency period is established. According to the
latency phase of EBV-associated malignancies, different
latent genes are expressed [2]. In latency type I, which is
represented by BL, only EBNA-1, EBER-and BART-RNAs
are expressed, while in latency type II, which is typical
for HL, NPC, gastric cancer and T-cell lymphomas, also
latent membrane protein 1 (LMP1) and 2A (LMP-2A)
are expressed. Additionally, type III latency, which occurs
in post-transplantation lymphoproliferative disease, is also
characterized by the expression of LMP1 and a variety oftd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cell lines (LCLs) serve as a model system for type III la-
tency. LCLs are usually derived from Epstein-Barr
virus (EBV) infection of resting human B lymphocytes
in vitro, resulting in continuous cell proliferation and
transformation.
Among the virus-encoded genes, LMP1 plays a critical
role in EBV-induced cellular transformation [1-4]. The
LMP1 oncoprotein, encoded by the BNLF-1 gene of EBV,
constitutes a transmembrane protein composed of 386
amino acids (aa) that contributes to the development of
EBV-associated tumors. Functionally, LMP1 mimics the
human CD40 receptor, a costimulatory receptor of the
tumor necrosis factor (TNF) receptor superfamily [5]. In
contrast to the ligand-dependent CD40, LMP1 drives pro-
liferation of infected B-cells independent of a ligand by
spontaneous formation of LMP1 oligomers. Two carboxy-
terminal cytoplasmic signaling domains, the C-terminal
activation regions 1 (CTAR1; aa 194–231) and 2 (CTAR2;
aa 351–386), are involved in activation of signaling path-
ways [6,7]. CTAR1 binds through a P(204)xQxT/S con-
sensus motif to TNF receptor-associated factors (TRAFs),
thereby inducing noncanonical (alternative) NF-κB signal-
ing through NF-κB-inducing kinase (NIK) and I-κB kinase
α (IKKα) [8-11]. Moreover, CTAR1 activates the p38
mitogen-activated protein kinase (MAPK), the phos-
phatidylinositol 3-kinase (PI3-kinase)/Akt pathway, and
can contribute to activation of the c-Jun N-terminal kin-
ase (JNK) pathway [12-14]. The signaling domain CTAR2
binds through tyrosine residue Tyr384 to TNF-receptor
associated death domain (TRADD), which is required for
canonical (classical) NF-κB activation and B lymphocyte
transformation [8,15,16]. TRAF6 and the tumor necrosis
factor-receptor-associated factor 2 (TRAF2)- and Nck-
interacting kinase TNIK have critical functions in NF-κB
signaling downstream of CTAR2 [12,17,18]. Additionally,
CTAR2 contributes to activation of p38 MAPK [12] and
triggers the JNK pathway [19].
The mechanisms by which LMP1 promotes tumori-
genesis are not fully understood. In addition to LMP1-
mediated alterations in cell growth and gene expression,
LMP1 also increases the expression of cytoskeletal pro-
teins and adhesion molecules [20], interacts with cytoskel-
etal components like vimentin [21], and causes plasma
membrane ruffling and villous projections [22]. In EBV-
transformed lymphocytes, the actin-bundling protein Fas-
cin (FSCN-1) is overexpressed in LCLs, while it is absent
in EBV-positive cell lines derived from BL [23]. Moreover,
Fascin is a possible prognostic marker of HL independent
of the presence of EBV [24], and it is upregulated in tis-
sues of NPC [25,26]. Fascin usually stabilizes filamentous
actin and is concentrated in cellular protrusions like filo-
podia during cell migration [27,28]. In healthy individuals,
Fascin is expressed in dendritic, neuronal, mesenchymaland endothelial cells, while it is absent from epithelial
cells and lymphocytes [27,29]. In contrast, Fascin is up-
regulated in many human carcinomas including breast,
lung, colon, esophagus, pancreatic, stomach, ovary, and
skin cancers. Fascin is concentrated in the leading edge
of cancer tissue, stabilizes invadopodia, and mediates
self-seeding of cancer cells [28,29]. We could previously
show that silencing of Fascin decreases not only the mi-
gratory and invasive capacity of cancer cells [28,29], but
also the invasion rate of cells derived from Adult T-cell
leukemia/lymphoma [30]. Recently, Fascin has received
attention as a potential prognostic marker and thera-
peutic target for metastasis [29,31].
Though there has been evidence for an association
between EBV-infection and Fascin expression, both the
mechanism of Fascin upregulation by EBV in lymphocytes
and Fascin’s function are still unclear. In this study we
show that LMP1 is sufficient to induce the tumor marker
Fascin in lymphocytes depending on NF-κB signaling.
We provide evidence that Fascin contributes to LMP1-
mediated invasive migration.
Results
Fascin is differentially expressed in transformed
lymphocytes
In search of the functional role of Fascin in EBV-transformed
lymphocytes, we started to analyze the expression pattern
of Fascin in a number of cell lines by quantitative PCR
(qPCR; Figure 1A). Human T-lymphotropic virus type 1
(HTLV-1)-transformed MT-2 cells, which express high
amounts of Fascin [30], served as a positive control. In
contrast to Jurkat T-cells, which only expressed very low
amounts of Fascin mRNA, EBV-transformed lymphoblas-
toid cell lines (LCLs) LCL-B and LCL-721 cells (latency
type III) expressed high amounts of Fascin; in LCL-3 and
LCL-4 (latency type III), expression of Fascin was en-
hanced as well, albeit to lower levels than in LCL-B and
LCL 721 cells. Cell lines derived from Hodgkin lymphoma
(HL; EBV-negative), including KM-H2, L428, and HDLM-
2, expressed high amounts of Fascin. All cell lines derived
from Burkitt lymphoma (BL; latency type I) did not ex-
press Fascin confirming earlier observations [23]. In B-cell
lymphoma cell lines derived from Kaposi’s sarcoma herpes
virus-associated malignancies like primary effusion lymph-
oma (PEL) including EBV-negative cell lines Bcbl-1 and
BC-3, and EBV-positive JSC-1 cells (latency type II),
Fascin was only detectable at low amounts in the PEL-
cell line JSC-1. This cell line is known to express low
amounts of LMP1, which can be detected by PCR, but
not at the protein level [32]. Data obtained by qPCR
(Figure 1A) were confirmed in immunoblots detecting
Fascin protein (Figure 1B). Among all cell lines ana-
lyzed, LCL-B, LCL-721, LCL-3 and LCL-4 cells are also
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Figure 1 Expression of Fascin in B-cell lymphomas. (A) Quantitative PCR (qPCR) of Fascin transcripts in transformed B-cells derived from
EBV-transformed lymphoblastoid cell lines (LCL), from Burkitt lymphoma (BL), Hodgkin lymphoma (HL), and from primary effusion lymphoma
(PEL) in comparison to Jurkat cells and Fascin-positive, HTLV-1-transformed MT-2 cells. Copy numbers were normalized to those of ß-Actin (ACTB)
and thereafter normalized to relative Fascin expression in Jurkat cells. The means of two independent experiments are shown. ctrl. indicates
control. (B) Detection of Fascin and LMP1 by immunoblot. In addition to the B-cell lines shown in (A), peripheral blood mononuclear cells (PBMC)
from a healthy donor were analyzed. Detection of ACTB served as loading control. Slower migrating bands upon detection of LMP1 reflect HA-LMP1.
(C) Immunofluorescence of EBV-transformed LCL-B cells spotted on fibronectin-coated coverslips using phalloidinX-TexasRed for detection of actin
and anti-Fascin and secondary anti-mouse Alexa Fluor® 488 antibodies. Nuclei were stained with DAPI. Images were acquired using a LAS AF DMI 6000
fluorescence microscope equipped with a 63 × 1.4 HCX PL APO oil immersion objective lens. Jurkat cells (mock) as shown in Figure 2B served as
negative control.
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of HL-derived cells [24], of LCLs, and of other LMP-1-
expressing cell lines (JSC-1). To analyze the subcellular
localization of Fascin in transformed, LMP-1 expressing
B-cells, immunofluorescence analysis was performed in
LCL-B cells (Figure 1C). Fascin was found in the cyto-
plasm and at the plasma membrane and colocalized with
actin, suggesting that Fascin exerts its molecular function
of stabilizing actin in EBV-transformed B-cells.
LMP1 is sufficient to induce Fascin in lymphocytes
LMP1 is a potent oncoprotein that contributes to cell
transformation and tumor formation by various means
(see Introduction). To evaluate whether LMP1 might
also be involved in Fascin upregulation observed in
LMP1-positive cells, we tested the potential of LMP1 to
induce Fascin expression by transfecting Jurkat cells
with expression constructs of LMP1 (HA-LMP1) or a
mock control (Figure 2A). Jurkat cells were chosen asthey express only low levels of endogenous Fascin and
they can be transfected efficiently. As a positive control
for Fascin induction served Jurkat cells transfected with
an expression plasmid for the HTLV-1 Tax oncoprotein,
which we previously identified as a specific and strong
inducer of Fascin [30]. Immunoblot analysis revealed
LMP1-mediated Fascin induction. Therefore, not only
the HTLV-1-encoded Tax, but also the EBV-encoded
LMP1 oncoprotein are potent inducers of Fascin. Im-
munofluorescence analysis revealed that Fascin local-
ized to the cytoplasm of LMP-1-transfected Jurkat cells
(Figure 2B), while mock-transfected cells did not show
Fascin expression. Co-staining of actin using TexasRed-
coupled phalloidin revealed that Fascin and actin coloca-
lized in LMP1-transfected Jurkat cells, which was further
supported by the profiles of the fluorescence intensity for
Fascin and actin staining (Figure 2C). These data show
that Fascin colocalizes with actin upon LMP1-expression
suggesting that both proteins could cooperate in exerting
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Figure 2 LMP1 induces Fascin in lymphocytes. (A) Detection of Fascin by immunoblot of Jurkat cells transiently transfected with wildtype
(wt-) LMP1 expression plasmid (pCMV-HA-LMP1) in comparison to mock-transfected (pcDNA3) and Tax-transfected Jurkat cells. As loading control
served detection of Hsp90 α/β. (B) Triple immunofluorescence staining and confocal microscopy of Jurkat cells transiently transfected with
wt-LMP1 expression plasmid (pCMV-HA-LMP1) in comparison to mock-transfected Jurkat cells. Cells were spotted on fibronectin-coated coverslips
using phalloidinX-TexasRed for detection of actin and anti-Fascin and secondary anti-mouse Alexa Flour® 488 antibodies. Nuclei were stained with
DAPI. Images were acquired using a Leica TCS SP5 confocal laser scanning microscope equipped with a 63 × 1.4 HCX PL APO CS oil immersion
objective lens (Leica). DIC indicates differential interference contrast, ROI, region of interest. (C) Profiles of the fluorescence intensities of Fascin
and actin plotted against the length of the ROI in Jurkat cells expressing LMP1 as shown in (B). (D) qPCR of Fascin in NGF-R:LMP1 LCLs (B2264-19/3) at
the indicated times after cross-linking with anti-NGF-R and anti-fc IgG/IgM antibodies. Copy numbers were normalized to those of ACTB. The means of
five independent experiments +/−SE were compared (t-test). *indicates P < 0.05.
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protein Fascin is specifically and strongly upregulated in
the presence of EBV/LMP1.
To confirm that Fascin is in fact an immediate-early cel-
lular target gene regulated by LMP1 in EBV-transformed
B lymphocytes, the LCL B2264-19/3 expressing a fusionprotein of the extracellular and transmembrane domains
of the human low-affinity nerve growth factor receptor
(NGF-R) and the cytoplasmic signaling domain of LMP1
(NGF-R:LMP1) in the context of the intact EBV genome
was analyzed (Figure 2D). B2264-19/3 cells were ge-
nerated by infection of primary human B-cells with
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had been replaced by NGF-R:LMP1 [34]. Aggregation of
NGF-R:LMP1 at the cell surface by antibodies induces
LMP1-specific signaling including activation of NF-κB,
p38MAPK, JNK1/2 and STAT1 [34]. To induce LMP1 sig-
naling, B2264-19/3 cells were either left untreated or
cross-linked with primary antibodies directed against
NGF-R and secondary anti-mouse antibodies. After isola-
tion of RNA and cDNA synthesis, qPCR analysis was per-
formed. In contrast to the unstimulated control cells, we
observed a significant increase of Fascin after 120 min of
cross-linking (Figure 2D; p < 0.05; t-test). Monitoring IκBα
degradation after NGF-R:LMP1 cross-linking confirmed
robust activation of the canonical NF-κB pathway by
NGF-R:LMP1 in B2264-19/3 cells (data not shown).
Thus, Fascin is also a cellular target gene of LMP1 signaling
in EBV-infected B-cells.
CTAR2 of LMP1 is the major site of Fascin induction
LMP1 specifically induces via its cytoplasmatic signaling
domains CTAR1 and CTAR2 defined signaling pathways
including NF-κB, JNK, PI3K/Akt and p38/MAPKK
(Figure 3A). To map the regions in the LMP1 protein that
mediate induction of Fascin expression, Jurkat cells were
transfected with wt-LMP1, the CTAR1-mutant HA-LMP1
(AAA), and the CTAR2-mutant HA-LMP1-Δ371-386.
Jurkat cells transfected with pcTax served as a positive
control for Fascin induction. Due to differences in LMP1
protein expression levels (data not shown), plasmids en-
coding LMP1 and the respective mutants had been ti-
trated to reach comparable amounts of LMP1 protein
expression. After 48 h, RNA was extracted and upon cDNA
synthesis, qPCR was performed (Figure 3B). Compared to
mock-transfected cells, LMP1 and Tax-1 induced Fascin
expression. Whereas expression of HA-LMP1(AAA) led
to slight induction of Fascin, expression of HA-LMP1-
Δ371-386 did not increase Fascin mRNA compared to
mock-transfected cells, indicating that (1) CTAR2 is es-
sential for LMP1-mediated Fascin induction, and (2)
CTAR1 contributes to Fascin mRNA induction (Figure 3B).
To account for different protein expression levels of the
LMP1 constructs, protein lysates were isolated in paral-
lel and subjected to Western blot analysis (Figure 3C).
Taking into consideration the lower protein expression
of HA-LMP1(AAA) compared to wt-LMP1 and the
CTAR2-mutant HA-LMP1-Δ371-386, we found that
only the CTAR2-mutant was insufficient to induce Fascin
protein. Experiments using a CTAR1/CTAR2-double mu-
tant failed as the expression of the double mutant was al-
ways much lower than expression of the single mutants
alone (data not shown). Therefore, these data show that
CTAR1 could contribute to LMP1-mediated Fascin induc-
tion (Figure 3B), whereas CTAR2 is the major and essen-
tial site of Fascin induction (Figure 3B,C).LMP1 stimulates Fascin expression via the NF-κB signaling
pathway
In addition to activation of the p38 MAPK and JNK
pathway [12,19], CTAR2 is required for LMP1-mediated
activation of the canonical NF-κB pathway [8,15,16]. To
test whether canonical NF-κB signals are required for
LMP1-mediated Fascin induction, LMP1 was either
cotransfected with a dominant negative inhibitor of ca-
nonical NF-κB signaling, pIκBα-DN (S32/36A) [35], or
Jurkat cells transfected with LMP1 were incubated in
the presence of the IKKβ-inhibitor ACHP. Concentrations
of ACHP were chosen such that they are not toxic to Jur-
kat cells and that they block canonical NF-κB signaling
[36]. RNA was extracted, subjected to cDNA synthesis
and analyzed in qPCR. The presence of pIκBα-DN re-
duced LMP1-mediated Fascin induction dose-dependently
(Figure 4A). Upon expression of 10 μg of the IκBα-DN
plasmid, LMP1-mediated Fascin induction was repressed
significantly (p < 0.01; t-test). Block of IKKβ using ACHP
(10 μM) also blocked LMP1-mediated Fascin induction
(p < 0.01; t-test) indicating that NF-κB signals are required
for expression of Fascin. Quantitation of transcripts of the
costimulatory tumor necrosis factor superfamily receptor
4-1BB (TNFRSF 9) in the same samples served as a posi-
tive control (Additional file 1). 4-1BB is a target of LMP1
and is induced by CTAR2 requiring canonical NF-κB sig-
nals [37]. Upon expression of LMP1, 4-1BB transcripts
were induced (p < 0.01, t-test) even at higher magnitudes
than Fascin. Both ACHP and IκBα-DN (10 μg) resulted in
significant reduction of LMP1-mediated 4-1BB induction,
demonstrating the successful repression of canonical NF-
κB signals. To further show that canonical NF-κB signals
are required for LMP1-mediated Fascin induction, protein
expression of LMP1 and Fascin was analyzed in western
blot analysis (Figure 4B). Detection of p100 and its pro-
cessing into p52 served as controls for the activity of ca-
nonical and non-canonical NF-κB signaling, respectively
(Figure 4B). LMP1 led to an increase in p100 expression
and p52 processing, reflecting activity of both NF-κB
signaling pathways. However, in the presence of ACHP
and IκBα-DN, only p100 was reduced, while processing
of p100 into p52 was unaffected, indicating that canonical
NF-κB signals were selectively blocked. In consistency
with the data observed on Fascin transcript levels
(Figure 4A), also Fascin protein (Figure 4B) was re-
duced by coexpression of pIκBα-DN (10 μg). Moreover,
inhibition of IKKβ by ACHP also abrogated LMP1-
mediated induction of Fascin protein. Despite a slight
but insignificant influence of inhibitor treatment on
LMP1 protein expression as measured by densitometry
(Figure 4B; n = 4; n.s., p > 0.05), Fascin was reduced
significantly in the presence of NF-κB inhibitors (Figure 4A).
Taken together, in addition to a functional CTAR2 domain
(Figure 3), an intact canonical NF-κB signaling pathway is
B**
Figure 3 CTAR2 is the major site of LMP1-mediated Fascin
induction. (A) Scheme of LMP1 and its signaling domains, the
C-terminal activating regions 1 (CTAR1; aa 194–231) and 2 (CTAR2; aa
351–386). Mutations of the P(204)xQxT consensus motif to AxAxA in
CTAR1 and deletion of aa 371–386 in CTAR2 are indicated. Signaling
pathways induced by LMP1 are shown in rectangular boxes, adaptor
molecules in rounded boxes. can. indicates canonical; noncan.,
noncanonical. (B) qPCR of Fascin transcripts 48 h after transfection
of Jurkat cells with wt-LMP1 (20 μg pCMV-HA-LMP1), LMP1 mutants
(40 μg pCMV-HA-LMP1(AAA), 20 μg of pCMV-HA-LMP1-Δ371-386) and
HTLV-1/Tax (40 μg pcTax-1) in comparison to mock-transfected cells
(100 μg pcDNA3). Total transfected DNA was adjusted to 100 μg with
pcDNA3. Copy numbers were normalized to those of ACTB and on
mock-transfected cells. Mean values +/− standard error (SE) are given.
(C) Detection of Fascin and LMP1 by immunoblot after transient
transfection of Jurkat cells with the constructs described in (B). Fascin
expression was quantitatively evaluated by densitometry and normalized
on LMP1 protein expression. The mean of three independent
experiments +/−SE is shown. **indicates P < 0.01. n.s., not significant.
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cells.
The NF-κB signaling pathway is required for Fascin
expression and invasive migration of EBV-transformed,
LMP1-expressing lymphoblastoid cells
To analyse whether canonical NF-κB signals are also
required for Fascin expression in EBV transformed
LMP1-expressing B-cells, LCL-B cells were incubated
with increasing amounts of the IKKβ-inhibitor ACHP
(Figure 5A-C). Treatment of cells with a selective in-
hibitor of the JNK pathway (SP600125; 10 μM) served
as specificity control [38]. After 48 h, viability of cells
was determined by flow cytometry and RNA was ex-
tracted. Forward-side-scatter (FSC/SSC) analysis revealed
that low concentrations of ACHP (1, 2.5, 5 μM) only
slightly affected viability of the LCL-B culture compared
to the solvent control DMSO (p > 0.05; paired t-test;
Figure 5A). However, high concentrations of ACHP (10,
25 μM) reduced viability of LCL by 50-75% (p < 0.05;
paired t-test) confirming earlier observations [39]. Quanti-
tation of Fascin copy numbers by qPCR showed that even
at low concentrations of ACHP (2.5, 5 μM), Fascin copy
numbers were significantly and dose-dependently reduced
(Figure 5B; p < 0.01; paired t-test), while inhibition of JNK
signaling with SP600125 did not affect Fascin expression.
To ensure specificity of the IKKβ-inhibitor ACHP in
LCLs, transcripts of the NF-κB-dependent LMP1-target
gene 4-1BB were measured (Additional file 2) [37]. Already
at low concentrations of ACHP (1μM), expression of 4-1BB
was diminished significantly (p < 0.01). While Fascin
was only affected by treatment with ACHP, 4-1BB was
also diminished upon treatment with the JNK-inhibitor
SP600125, which confirms earlier findings showing a
role of both NF-κB and JNK signaling in 4-1BB regulation
[40]. To further address the influence of NF-κB signals on
n . s .    p > 0 . 0 5
Figure 4 NF-κB signals are required for LMP1-mediated Fascin
induction. (A) Quantitative PCR of Fascin mRNA in Jurkat cells after
transfection of wt-LMP1 (pSV40-LMP1) and co-transfection of
pIκBα-DN or treatment with the IKKβ inhibitor ACHP
(2-Amino-6-(2-(cyclopropylmethoxy)-6-hydroxyphenyl)-4-(4-piperidinyl)-
3-pyridine-carboni-trile) solved in DMSO. ACHP (10 μM) was added 24
h after transfection for 24 h. Relative copy numbers were determined
by normalizing Fascin transcripts to those of ACTB. Mean values +/− SE
were compared using a t-test (n = 4). **indicates P < 0.01. (B) Immunoblot
of Fascin, LMP1, p100, p52, and ACTB (ß-Actin) in Jurkat cells after
transfections as described in (A). LMP1 expression was quantitatively
evaluated by densitometry and normalized on ACTB protein expression.
The mean of four independent experiments +/−SE is shown and was
compared (t-test, n = 4, P > 0.05). n.s. indicates not significant.
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treatment of LCLs with low doses of ACHP (2.5 μM;
5 μM). These data revealed that also Fascin protein is re-
duced upon treatment of LCLs with ACHP, despite thepresence of LMP1 (Figure 5C). Beyond that, treatment of
LCLs with ACHP led to less production of p100, a clas-
sical target of canonical NF-κB signaling, while processing
of p100 to p52 was not affected. Finally, we observed an
accumulation of IκBα, suggesting that (1) IκBα gets less
degraded in presence of ACHP, and that (2) canonical NF-
κB signals are blocked. In summary, these data show that
Fascin is regulated by canonical NF-κB signals not only
in LMP1-transfected cells, but also in LMP1-expressing,
EBV-transformed lymphoblastoid B-cells.
Fascin contributes to invasion of cancer cells [28,29,41]
and HTLV-1-transformed T lymphocytes [30], however,
the relative contribution of Fascin to the motility of EBV-
transformed lymphocytes has not been investigated. To
analyse whether inhibition of NF-κB, which leads to re-
duction of Fascin (Figure 5C), also affects invasion of
EBV-transformed lymphocytes, LCL-B cells were incubated
in the presence of ACHP (5 μM, 48 h) and serum-starved
for 4 h. Subsequently, invasion assays were performed util-
izing basement-membrane coated inserts which separate
the cells from medium with 20% fetal calf serum (FCS) in
the lower well. Invasive cells are able to degrade the
matrix, pass through the pores of the polycarbonate mem-
brane, and attach either to the bottom of the membrane
(Figure 5D, upper panel), or they migrate to the lower well
after invasion (Figure 5D, lower panel). We did not detect
different numbers of cells attached to the bottom of the
membrane (Figure 5D, upper panel; n = 3; t-test; p > 0.05).
This suggests that inhibition of NF-κB does not affect ad-
hesion of invaded LCLs to the membranes used in our
assay. However, we observed that the number of invaded
and non-attached LCLs in the lower well was significantly
reduced to approximately 11% in presence of ACHP com-
pared to the solvent control (Figure 5D, lower panel; n = 3;
t-test, p < 0.05). We observed slight reduction of cell vital-
ity in presence of the inhibitor (Figure 5A, compare 5 μM
ACHP and DMSO; p > 0.05), but we measured significant
impairment of NF-κB activity and Fascin expression
(Figure 5B, C). Therefore, we conclude that inhibition
of NF-κB significantly reduces the migratory rate of LCLs
subsequent to invasion of the extracellular matrix, and
Fascin might contribute to this phenotype.
Knockdown of Fascin reduces the invasive capacity of
LMP1-expressing lymphocytes.
In studies focusing on NPC and cells of epithelial origin,
LMP1 has been described as a potent regulator of cellular
migration and invasion [42–45]. To test, whether sole ex-
pression of LMP1 induces invasion of lymphocytes, too,
and whether this specifically depends on Fascin, invasion
assays were performed in transiently transfected cells. For
this purpose, Jurkat cells were transfected with LMP1-
expression plasmids, two different shRNA-constructs tar-














Figure 5 NF-κB signals are required for maintaining Fascin expression and invasive migration of EBV-transformed LMP1-expressing
lymphoblastoid cells (LCL). (A) Viability of LCL-B cells upon treatment with increasing amounts of the IKKβ inhibitor ACHP (1, 2.5, 5, 10, 25 μM)
and the JNK-inhibitor SP600125 (10 μM) for 48 h determined by forward-side scatter (FSC/SSC) analysis in flow cytometry. DMSO-treated cells
were set as 100%. The means of three independent experiments +/− SE were compared using a paired t-test. *indicates P < 0.05. (B) Quantitative
PCR of Fascin transcripts normalized to ACTB in LCL-B upon ACHP-and SP600125-treatment for 48 h. The means of three independent
experiments +/− SE were normalized to solvent-treated cells and compared using a paired t-test. **indicates P < 0.01. (C) Detection of Fascin, LMP1,
p100 processing (p100/p52) and IκBα by immunoblot after treatment of LCL-B with DMSO, 2.5 and 5 μM ACHP for 48 h. ACTB served as loading
control. Samples were loaded on two gels in parallel. (D) LCL-B cells were cultured in presence of ACHP (5 μM) or solvent (DMSO) for 48 h and cells
were serum-starved (1% fetal calf serum (FCS)) for 4 h. Invasion assays were performed using trans-wells coated with extracellular matrix for 24 h. Values
shown in the upper panel reflect the percentage of invaded cells (measured at OD 560 nm) that are attached to the bottom of the membrane. The
lower bar graphs show the percentage of invaded cells that are non-attached and have migrated to the medium (20% FCS) of the lower compartment.
Solvent-treated cells (DMSO) were set as 100%. Mean values and error bars of three independent experiments each performed in triplicates are shown.
Values were compared using a paired t-test. *indicates P < 0.05. n.s., not significant.
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analysis, cells were co-transfected with an expression
plasmid for LNGFR, which encodes a cytoplasmic trun-
cated, low-affinity nerve growth factor receptor that is not
expressed on Jurkat cells (data not shown), and therefore
allows positive selection of transfected cells by mag-
netic separation. Flow cytometry using LNGFR-specificantibodies revealed that the amount of LNGFR-expressing
cells was enriched by magnetic separation from approxi-
mately 33% to ca. 82%, independent of the combination of
co-transfected plasmids (Additional file 3). Upon enrich-
ment, a robust Fascin induction by LMP1 was observed in
the presence of non-targeting control shRNA (Figure 6A,















































Figure 6 Knockdown of Fascin in LMP1-transfected Jurkat cells diminishes invasion through extracellular matrix. (A) Jurkat cells were
transfected with pMACS-LNGFR, wt-LMP1 (pSV-LMP1) and shFascin5, shFascin4 or shNonsense (shNon) and subjected to magnetic separation.
Immunoblots of Fascin, LMP1 and ACTB are shown. Numbers indicate the relative expression of Fascin normalized on ACTB as determined by
densitometry (at least 4 experiments). Values obtained from cells transfected with LMP1 and a control shRNA (shNon) were set as 1. indicates
cross reactions of the LMP1-antibody. (B) Invasion assays were performed with serum-starved Jurkat cells (1% FCS) after magnetic separation
using trans-wells coated with extracellular matrix for 24 h. Values shown in the upper panel reflect the percentage of invaded cells (measured at
OD 560 nm) that are attached to the bottom of the membrane. The lower bar graphs show the percentage of invaded cells that are non-attached
and have migrated to the medium (20% FCS) of the lower compartment. Mock-transfected cells were set as 100%. Mean values and error bars of three
independent experiments each performed in quadruplicates are shown. Values were compared using a paired t-test. **indicates P < 0.01. *indicates
P < 0.05. n.s., not significant.
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(from 4.69 to 0.63) or 77% (from 4.69 to 1.10), respect-
ively. Cells were serum-starved for 5 h in 1% FCS and
invasion assays were performed utilizing basement-membrane
coated inserts which separate the cells from medium
with 20% FCS in the lower well as described in Figure 5D.
Although we did not detect a significantly increased
number of cells attached to the bottom of the membrane
(Figure 6B, upper panel; n = 3; t-test; p > 0.05), we ob-
served that expression of LMP1 significantly enhanced
the number of invaded and non-attached Jurkat cells in
the lower well to approximately 158% compared to the
mock control (100%); (Figure 6B, lower panel; n = 3;
t-test, p < 0.01). Functional knockdown of Fascin using
shFascin 5 or shFascin 4 reduced the amount of invaded,
non-attached cells to 105% or 103%, respectively (n = 3; t-
test, p < 0.05), demonstrating that Fascin strongly contrib-
utes to the increasing number of cells migrated to the
lower well. Therefore, our data suggest that neither LMP1
nor Fascin affect adhesion of invaded lymphocytes to the
membranes used in our assay. However, LMP1 enhances
the migratory rate of Jurkat cells subsequent to invasion
of the extracellular matrix, and Fascin accounts primarily
for this phenotype. Taken together, we conclude that the
viral oncoprotein LMP1 is sufficient to induce the tumormarker Fascin dependent on canonical NF-κB signals,
which could contribute to invasive migration.
Discussion
The tumor marker Fascin is an actin-bundling protein
related to migration and invasion in an increasing num-
ber of neoplastic diseases [28,29,41]. Here we show that
the EBV-encoded oncogene LMP1 induces the tumor
marker Fascin in lymphocytes. Induction of Fascin by
LMP1 strongly depends on an intact CTAR2 domain as
demonstrated by ectopic expression of LMP1-mutants.
Canonical NF-κB signaling plays an important role in
LMP1-mediated induction of Fascin in both transfected
and transformed, LMP1-expressing lymphocytes. In func-
tional analyses, we show that canonical NF-κB signaling
and Fascin expression contribute to invasive migration of
LMP1-expressing lymphocytes through the extracellular
matrix.
There has been evidence that Fascin is expressed in
EBV-transformed lymphoblastoid cell lines (LCLs) [23],
which is confirmed in this study. Our data showing that
Fascin is a cellular target gene immediately induced by
LMP1 signaling in LCLs could explain this phenotype.
In contrast, EBV-positive Burkitt Lymphoma (BL)-de-
rived cell lines, which are known to be LMP1-negative
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for Hodgkin’s lymphoma (HL)-derived cells used in our
study, which express high amounts of Fascin although
they are LMP1-negative. Expression of Fascin had been
described earlier in cutaneous CD30+ lymphoprolifera-
tive disorders [46], and in HL-derived Reed-Sternberg
cells [24]. Fascin was discussed as a prognostic marker
of HL [24]. Despite the absence of LMP1, both the canon-
ical and noncanonical NF-κB pathways are constitutively
activated in HL due to genetic lesions, auto-and paracrine
signals, and expression of TNF receptor (TNFR) family
members [47]. Moreover, aberrant activation of the NF-κB
pathway is of key importance for the survival of HL-
derived cells [47]. Therefore, constitutive activation of
NF-κB could explain high expression levels of Fascin in
the absence of LMP1 in HL-derived cells requiring fur-
ther investigation. On the other hand, NF-κB activity
does not automatically result in expression of Fascin as
both Bjab and primary effusion lymphoma (PEL) cells
do not express Fascin despite high levels of NF-κB activity
[48,49]. However, our data show that NF-κB is necessary
for Fascin induction by LMP1 and Fascin expression in
LMP1-transformed LCLs, but it may not be sufficient in
other types of transformed B-cells.
Our findings show a direct link between LMP1 ex-
pression and the induction of Fascin in both B and T
lymphocytes. These observations are in line with find-
ings describing the presence of Fascin in lymph node
metastases in NPC. Fascin expression positively corre-
lated with the expression of both LMP1 and the phos-
phorylated transcription factor signal transducer and
activator of transcription 3 (STAT3), as well as with the
proliferation index of the tumor cells [25]. Collectively,
LMP1-mediated induction of Fascin may not only be re-
stricted to lymphocytes but also be applicable to cells of
epithelial origin, which suggests that LMP1-mediated
induction of Fascin is a general phenomenon of EBV-
biology.
LMP1 is not only expressed in latently infected B-cells,
but can also be upregulated during the lytic cycle in both
epithelial cells and B-cells. LMP1 seems to play a role in
virus production, as LMP1-deleted EBV enters the lytic
replication cycle as efficiently as the wild-type counterpart,
but is severely impaired in virus release into culture super-
natants [50], pointing to a defect in particle transport.
LMP1-mediated expression of the actin-bundling protein
Fascin in the cytoskeleton and its continuous expression
suggest a role of Fascin in virus release. This is further
corroborated by the finding that cell-to-cell transmission
of EBV to epithelial cells also depends on canonical NF-
κB signaling [51], which is also a prerequisite for efficient
Fascin induction.
Our data showing enhanced invasive migration of
lymphocytes in the presence of Fascin suggest that EBVexploits functions of Fascin. The capacity of Fascin to
induce migration of tumor cells could also be relevant
to the migratory capacity of EBV-transformed cells and
to EBV-associated disease, however, it remains to be de-
termined whether Fascin is essential for invasive migra-
tion of LCLs, as it is in LMP1-expressing Jurkat cells.
Our data show that block of canonical NF-κB signaling
reduces both Fascin and invasive migration of EBV-
transformed LCLs, thus, strengthening the assumption
that Fascin contributes to invasive migration of LCLs,
too. However, canonical NF-κB signaling also affects the
expression of other proteins than Fascin that could con-
tribute to cellular motility as well. Yet, selective repression
of Fascin in LMP1-expressing Jurkat T lymphocytes re-
vealed that in this cell type Fascin contributes to invasive
migration. As yet, it was known that LMP1 is a potent
regulator of cellular migration and invasion since LMP1
is capable of inducing a wide range of cellular factors in-
volved in tumor metastasis [42]. Both LMP1-mediated
transcriptional, posttranscriptional and posttranslational
regulation of cellular targets could contribute to the
capacity of LMP1 to promote spreading of tumor cells:
(1) LMP1 causes loss of junctional plakoglobin in naso-
pharyngeal carcinoma (NPC) cells and initiates a cadherin
switch [52]. (2) LMP1 upregulates decoy receptor 3, a
member of the TNFR superfamily, which enhances
NPC cell migration and invasion [43]. (3) LMP1 down-
regulates E-cadherin gene expression and induces cell
migration activity by using cellular DNA methylation
machinery [45]. (4) In NPC cells, LMP1 increases phos-
phorylation of the membrane cross linker ezrin through a
protein kinase C (PKC) pathway. Recruitment of ezrin to
the cell membrane linked to F-actin and CD44 is a process
required for LMP1-stimulated cell motility and invasion
of NPC cells [42]. We now show that LMP1 can also in-
duce the actin-bundling Fascin, which is strongly associ-
ated with migration and invasion in many types of cancer
[27-29]. In contrast to previous studies, which mainly fo-
cused on cells of epithelial origin and NPC [42,43,45], we
now show in T lymphoid cells that LMP1 is also import-
ant for invasive migration, whereas it seems to be dispens-
able for attachment of invaded cells. Beyond that our data
highlight for the first time an important role of Fascin in
LMP1-mediated invasive migration. Interestingly, LMP1’s
capacity to enhance migration is regulated by PI3K/Akt
and also by IκBα-dependent canonical NF-κB signaling in
NPC cells [44]. Thus, LMP1-mediated induction of NF-κB
also appears to contribute to LMP1-induced cell migra-
tion in lymphocytes, in particular by regulation of Fascin.
Activation of the NF-κB pathway is linked to LMP1-
induced immortalization of primary B lymphocytes. Al-
though signaling via CTAR2 mainly induces canonical
NF-κB signaling and production of p100, CTAR2 is not
sufficient for transformation in the absence of CTAR1.
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and induces noncanonical NF-κB signaling resulting in
processing of p100, but is sufficient for initial transform-
ation (reviewed in [6]). We show by three approaches
that canonical NF-κB signals are important for LMP1-
mediated Fascin induction: (1) A mutation of CTAR2
that is defective in NF-κB-signaling [33] failed to induce
Fascin, (2) Use of a super-repressor of NF-κB blocked
LMP1-mediated Fascin-induction, and (3) chemical block
of IKKβ reduced canonical NF-κB signaling and Fascin ex-
pression in both LMP1-transfected and LMP1-transformed
lymphocytes. Earlier studies have shown that Fascin har-
bours κB consensus sites in its promoter [53], and we have
shown that Fascin expression can be induced by NF-κB
[30]. Contribution of NF-κB to expression of Fascin was
also confirmed in a breast cancer cell line showing binding
of p65 to the Fascin promotor [54]. Collectively, these
findings suggest that LMP1 regulates Fascin expression
via canonical NF-κB signaling not only in lymphocytes,
but potentially also in other cell types.
We have previously shown that Fascin expression can
be induced by the viral oncoprotein Tax of the tumor
virus Human T-lymphotropic virus type 1 (HTLV-1),
which belongs to the family of delta-retroviridae [30].
Beyond that, we found a novel mode of transcriptional
regulation of Fascin showing the importance of NF-κB
signaling in Tax-mediated Fascin induction [30]. There-
fore, the LMP1-mediated induction of Fascin via NF-κB
signaling may be a common mechanism of lymphotropic
tumor viruses revealing a new quality of virus-induced
oncogenesis. All tumor viruses with naturally occurring
distinct oncogenes reprogram persistently infected cells
in the direction of growth promotion and survival func-
tions, and it is plausible that these are side effects of
viral growth and propagation. Now, we have shown
that not only the leukemia-inducing retrovirus HTLV-
1, but also the oncogenic herpesvirus EBV can induce
Fascin. However, future studies are needed to address
whether other viral oncoproteins like the KSHV-encoded
oncoprotein vFLIP, which activates both canonical and
non-canonical NF-κB pathways [49], are able to induce
Fascin. In contrast to LCLs, PEL cells do not express
Fascin, suggesting that regulation of Fascin does not
only depend on cell type and on the NF-κB signaling
pathway, but also on other properties of different viral
oncoproteins.Conclusions
Here we report for the first time that LMP1 induces Fascin
in lymphocytes and this depends on canonical NF-κB sig-
naling. Fascin mediates invasiveness of carcinoma cells, a
typical function of tumor progression. Our data indicate a
contribution of Fascin to invasive migration of LMP1-expressing lymphocytes. Collectively, our findings suggest
that Fascin plays a role in viral oncogenesis.Methods
Cell culture
Cell lines used in this report include the Epstein-Barr
virus-positive (EBV+) human lymphoblastoid B-cell lines
(LCLs) LCL-B (provided by G. Niedobitek) and LCL-721
[55]; the EBV+ LCLs LCL-3 and LCL-4, which are derived
from in vitro transformation of human B lymphocytes
with a recombinant maxi-EBV in which the wildtype
LMP1 gene had been replaced by HA-LMP1 [33]; the LCL
clone B2264-19/3 expressing chimeric nerve growth factor
receptor (NGF-R):LMP1 allowing inducible LMP1 signal-
ing [34]; the EBV-negative (EBV−) Hodgkin lymphoma
(HL)-derived cell lines KM-H2 [56,57], L428 [58], and
HDLM-2 [59,60]; the EBV+, Burkitt Lymphoma (BL)-de-
rived B-cell line Raji [61]; the EBV−, BL-derived B-cell line
Bjab [62], and the EBV− B-cell line Akata (an Akata sub-
clone that has lost the virus) [63]; the EBV−, Kaposi’s
sarcoma-associated herpesvirus-positive (KSHV+) B-cell
lines Bcbl-1 [64] and BC-3 [65] derived from primary ef-
fusion lymphoma (PEL); the EBV+ KSHV+ PEL-derived
B-cell line JSC-1 [32]; the Human T lymphotropic virus
type 1 (HTLV-1) in vitro transformed CD4+ T-cell line
MT-2 [66]; and the acute lymphoblastic leukemia T-cell
line Jurkat [67]. LCL-B-cells were cultured in RPMI 1640M
containing fetal calf serum (FCS), 50 μM β-mercaptoethanol
(GIBCO, Life Technologies, Darmstadt, Germany), 1 mM
sodium pyruvate (GIBCO), glutamine, and penicillin/
streptomycin. LCL-721, LCL-3, LCL-4, and MT-2 cells
were cultured in RPMI 1640M, 10% FCS, glutamine
(0.35 g/L) and penicillin/streptomycin. B2264-19/3 B-cells
expressing NGF-R:LMP1 were cultivated on γ-irradiated
CD40L-expressing fibroblast feeder cells in RPMI 1640M
containing 10% FCS, 100 nM sodium selenite (Sigma-Al-
drich), 1% sodium pyruvate, 0.5 mM monothioglycerol
(Sigma-Aldrich), 0.02 μM bathocuproinedisulfonic acid
(Sigma-Aldrich) and penicillin/streptomycin. All other cell
lines were cultured in RPMI 1640M containing 45% Pan-
serin 401 (PAN-Biotech, Aidenbach, Germany), 10% FCS,
glutamine (0.35 g/L) and gentamycine. Peripheral blood
mononuclear cells (PBMC) were isolated from buffy coats
of anonymized healthy donors (Institut für Transfusions-
medizin, Suhl, Germany) by Ficoll-Hypaque gradient cen-
trifugation (Biocoll, Biochrom, Berlin, Germany). Informed
consent was not requested as the data were analyzed an-
onymously and the samples had not been collected spe-
cifically for this study. This procedure was approved by
the Ethics Committee of the Medical Faculty of Friedrich-
Alexander-Universität Erlangen-Nürnberg (Erlangen,
Germany). PBMC were cultured in RPMI 1640M con-
taining 10% FCS, glutamine, penicillin/streptomycin,
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and interleukin-2 (25 U/ml) for 48 h.
Construction of shRNA expression vectors
For knock-down of Fascin by RNA interference (RNAi),
the retroviral shRNA expression vectors pSiren-IRES-
EGFP-shFascin5 (shFascin5) [30], and pSiren-IRES-EGFP-
shFascin4 (shFascin4) were constructed. Oligonucleotides
for shRNAs were designed with the siRNA Hairpin
Oligonucleotide Sequence Designer Tool (Clontech). They
contained (5′ to 3′) a BamHI site, the respective siRNA
sequence (bold), a loop region, the complementary siRNA
sequence (bold), an RNA polymerase III termination
sequence, an MluI restriction enzyme site (italicized),





GCg-3′) Oligonucleotides were annealed in 10 mM Tris
and 20 mM NaCl (pH 7.6) by heating to 95°C for 2
min followed by cooling to room temperature. Double-
stranded oligonucleotides were thereafter inserted into the
retroviral vector pSiren-IRES-EGFP-shNonsense (shNon)
[68] using T4 ligase (DNA Ligation kit, TaKaRa Biomedicals,
Gennevilliers, France) after removal of the shNon frag-
ment via BamHI and EcoRI restriction sites. The resulting
shRNA expression plasmid was called pSiren-IRES-EGFP-
shFascin4 (target at position +1407 of the Fascin coding
sequence, gene bank accession number NM_003088).
Immunoblots
Protein lysates were obtained by lysis of cells in 150 mM
NaCl, 10 mM Tris pH 7.0, 10 mM EDTA, 1% Triton, 2 mM
dithiothreitol (DTT) and protease inhibitors (20 μg/ml
Leupeptin, 20 μg/ml aprotinin and 1 mM phenyl-methyl-
sulfonyl fluoride). After repeated freeze-and-thaw cycles,
equal amounts of protein were denatured for 5 min at 95°C
in sodium dodecyl sulfate (SDS) loading dye (10 mM Tris
pH 6.8, 10% glycerine (w/v), 2% SDS (w/v), 0.1% brom-
phenol blue (v/v), 5% β-mercaptoethanol (v/v)) and
subjected to SDS- polyacrylamide gel electrophoresis
(SDS-PAGE) followed by immunoblotting on Nitrocel-
lulose Transfer Membranes (Whatmann ®, PROTRAN ®,
Whatmann GmbH, Dassel, Germany). Immunoblots were
probed using the rabbit monoclonal antibody anti-NF-κB2
p100/p52 (18D10; 1:1000, Cell Signaling Technology, MA,
USA) and mouse monoclonal antibodies anti-Fascin (55K-
2; 1:1000; Dako Deutschland GmbH, Hamburg, Germany),
anti-β-actin (ACTB; AC-15; 1:2500; Sigma, Taufkirchen,
Germany), anti-Hsp90α/β (F-8; 1:1000; Santa Cruz Biotech-
nology, Heidelberg, Germany), anti-LMP1 (clones CS.1-4;
1:100; Dako, Hamburg, Germany), anti-IκB-α (H-4; 1:1000;
Santa Cruz Biotechnology) and mouse antibodies to Tax(1:50), which were derived from the hybridoma cell line
168B17-46-34 (provided by B. Langton through the AIDS
Research and Reference Reagent Program, Division of
AIDS, NIAID, NIH) [69]. Secondary antibodies conjugated
with horseradish peroxidase were obtained from GE
Healthcare (Little Chalfont, UK). Peroxidase activity was
detected by enhanced chemiluminescence using a Kodak
Image Station 4000MM PRO camera (Kodak). In some
experiments, proteins were blotted on PVDF membranes
(Immobilon-FL, Merck Millipore, Billerica, MA, USA)
pre-incubated in methanol and goat anti-mouse Alexa
Fluor® 647-labelled secondary antibodies (1:2000; Life
Technologies) were used. Fluorescence intensity was de-
tected using Kodak Image Station 4000MM PRO camera.
At least three independent experiments were performed
and one representative result is shown. Intensities of spe-
cific bands were quantitated using Advanced Image Data
Analyser (AIDA Version 4.22.034, Raytest Isotopenmess-
geräte GmbH, Straubenhardt, Germany) and the mean of
at least three independent experiments is shown.
Immunofluorescence and confocal laser scanning
microscopy
Cells were spotted on 10 μg/mL fibronectin-coated
(Sigma) coverslips, fixed with 4% para-formaldehyde (20
min), washed twice with PBS and permeabilized with
0.2% Triton X-100 (20 min, 4°C). After four wash steps,
unspecific binding was blocked by 5% FCS/ 1% BSA in
PBS (1 h, 20°C). Cells were incubated with anti-Fascin
mouse monoclonal antibodies (1:100; Dako) for 30 min
at 37°C. After washing, cells were incubated with Alexa
Fluor® 488-conjugated goat anti-mouse IgG secondary
antibodies (Life Technologies) for 30 min at 37°C. For
double-labelling with filamentous actin, cells were co-
incubated with Texas Red-X phalloidin (1:20; Life Tech-
nologies). For staining of nuclei, cells were incubated with
VECTASHIELD Mounting Medium with DAPI (Vector
Laboratories, Burlingame, CA, USA). Images were ac-
quired using a LAS AF DMI 6000 fluorescence microscope
equipped with a 63 × 1.4 HCX PL APO oil immersion ob-
jective lens (Leica Microsysteme Vertrieb GmbH, Wetzlar,
Germany). Alternatively, images were acquired using a
Leica TCS SP5 confocal laser scanning microscope equipped
with a 63 × 1.4 HCX PL APO CS oil immersion objective
lens (Leica). Images were analyzed and signal intensities
were quantified using LAS AF software (Leica).
Quantitative real-time RT-PCR (qPCR)
Total cellular RNA was isolated from cell lines or trans-
fected cells (RNA isolation Kit II, Macherey-Nagel, Düren,
Germany; RNeasy micro Kit; Qiagen, Hilden, Germany)
and reversely transcribed to cDNA using Superscript II
and random hexamer primers (both Life Technologies
GmbH, Darmstadt, Germany) or QuantiTect Reverse
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real-time RT-PCR (qPCR) was performed in an ABI Prism
7500 Sequence Analyzer (Applied Biosystems, Foster City,
CA) using 200 ng of cDNA and SensiMix™ II Probe Kit
(Bioline GmbH, Luckenwalde, Germany) according to
the manufacturer’s instructions. Primers and FAM (6-
carboxyfluorescein)/TAMRA (tetramethylrhodamine)-
labeled probes for detection of β-actin (ACTB) transcripts
and 4-1BB have been described before [70]. For quanti-
tation of Fascin transcripts, a TaqMan Gene Expression
Assay (Hs00979631_g1; Applied Biosystems) was used.
Expression levels were computed by interpolation from
standard curves generated from plasmids carrying the
respective target sequences and calculating the mean
of triplicate samples. Each sample was measured in at
least three biological replicates. ACTB was used for
normalization.
Inhibitor treatment of LCL-B
LMP1-positive, EBV-transformed LCL-B cells were incu-
bated with increasing amounts (0, 2.5 μM, 5 μM, 10 μM;
25 μM) of an inhibitor of IκB kinase β (IKK-β), ACHP
(2-Amino-6-(2-(cyclopropylmethoxy)-6-hydroxyphenyl)-
4-(4-piperidinyl)-3-pyridinecarboni-trile); Calbiochem/
Merck, Darmstadt, Germany), dissolved in DMSO. After
48 h, RNA was extracted and viability of cells was deter-
mined analyzing forward versus side scatter (FSC vs. SSC)
using an BD Accuri C6 flow cytometer (BD Biosciences,
San Jose, CA, USA). A JNK-specific inhibitor SP600125
(10 μM) was used as control. Protein lysates were ob-
tained from cells after treatment with DMSO and ACHP
(2.5 μM, 5 μM) for 48 h.
Transient transfection by electroporation
107 Jurkat T-cells were transfected by electroporation
using Gene Pulser X® Electroporation System (BioRad,
Munich, Germany) at 290 V and 1500 μF with 20 μg
pCMV-HA-LMP1, 40 μg pCMV-HA-LMP1(AAA), 20
μg pCMV-HA-LMP1-Δ371-386 [16,33] or 40 μg pcTax-
1 [30]. pCMV-HA-LMP1(AAA) is mutated in CTAR1
and the PxQxT TRAF-binding motif is substituted by al-
anines (AxAxA) [16], while HA-LMP1-Δ371-386 carries
a deletion of the carboxy-terminal cytoplasmic region in
CTAR2 and is incapable of recruiting TRADD and
TNIK [18,33]. Total transfected DNA was adjusted to
100 μg with pcDNA3 (Life Technologies GmbH). In ex-
periments where NF-κB signaling was blocked, 107 Jurkat
cells were transfected with 40 μg of an SV40-promoter-
driven LMP1-construct, pSV-LMP1 [19], and 2 μg or 10 μg
of a dominant negative inhibitor of IκBα (pIκBα-DN;
S32/36A), a plasmid carrying two mutations at critical
serine residues S32 and S34 that are usually phosphory-
lated by IKKβ, thereby leading to proteasomal degrad-
ation of IκBα [35]. Total transfected DNA was adjustedto 50 μg with pcDNA3. In transient transfections, the
IKK-β-inhibitor ACHP (2.5 μM; 10 μM) was added 24 h
post transfection for 24 h. Cells were harvested 48 h
after transfection to isolate RNA and to perform im-
munoblots. For invasion assays, Jurkat cells were trans-
fected with 10 μg pMACS-LNGFR (Miltenyi Biotec,
Bergisch Gladbach, Germany), 40 μg pSV-LMP1 [19],
20 μg pSiren-RetroQ-IRES-EGFP-shNonsense (sh Nons),
pSiren-RetroQ-IRES-EGFP-shFascin5 (shFascin 5), or pSiren-
RetroQ-IRES-EGFP-shFascin4 (shFascin 4). Total trans-
fected DNA was adjusted to 100 μg with pcDNA3.
Cross-linking of NGF-R:LMP1
Prior to cross-linking of NGF-R:LMP1, B2264-19/3 cells
were cultivated in the absence of CD40L feeder cells for
three days. For NGF-R-cross-linking the cells were incu-
bated in culture medium supplemented with 1 μg/ml
anti-NGF-R for 30 minutes at 37°C. Cross-linking was
performed in the presence of 10 μg/ml anti-fc IgG/IgM
(115-005-068; Dianova) for the indicated times as de-
scribed [34].
Magnetic separation
To enrich LMP1-expressing cells, Jurkat cells co-
transfected with pMACS-LNGFR were washed with
PBS (without Ca2+ and Mg2+) 48 h post transfection,
and stained with anti-LNGFR-PE conjugated antibodies
(ME20.4-1.H4; 1:10; Miltenyi Biotec) for 10 min (4°C),
followed by an incubation with anti-PE MicroBeads
(Miltenyi Biotec) for 15 min (4°C). Labeled cells were
separated using MACS LS columns (Miltenyi Biotec)
on a MidiMACS™ Separator (Miltenyi Biotec). The per-
centage of cells stained for LNGFR was determined with
the BD Accuri C6 flow cytometer (BD Biosciences) before
and after magnetic separation.
Invasion assay
After magnetic separation LNGFR-enriched Jurkat cells
were serum-starved in cell culture medium containing
1% FCS for 4 h. LCL-B cells were cultured in presence
of 5 μM ACHP or DMSO for 48h prior to serum starva-
tion. Invasion assays were performed using CytoSelect™
24-Well Cell Invasion Assay (colorimetric format, Cell
Biolabs Inc., San Diego, CA) according to the manufac-
turer’s instructions. Briefly, cells were counted and 2 ×
105 Jurkat cells or 1.5 × 105 LCL-B cells in 300 μl
medium (1% FCS) were applied to the upper chamber of
a trans-well containing polycarbonate membranes with 8
μm pore sizes covered with extracellular matrix isolated
from mouse Engelbreth-Holm-Swarm sarcoma. The lower
chamber contained cell culture medium supplemented
with 20% FCS. Cells were incubated at 37°C for 24 h. After
aspirating media from the inside of the insert and cleaning
the inside with cotton-tipped swabs, the inserts were
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with Extraction Solution. Finally the OD 560 nm of the
cell extraction solution was measured with Emax precision
microplate reader (MWG-Biotech GmbH, Ebersberg,
Germany) reflecting the amount of invaded cells at-
tached to the bottom of the membranes. At least three
independent experiments were performed in quadru-
plicates (Jurkat) or triplicates (LCL-B). Invaded cells in
the lower compartment (non-attached cells) were counted
in at least four visual fields using a Neubauer chamber in
quadruplicates (Jurkat) or triplicates (LCL-B) in at least
three independent experiments.Statistics
SPSS version 16.0.2 (SPSS, Chicago, IL) was used for statis-
tical analysis using the t-test. P < 0.05 was considered to
be significant.Additional files
Additional file 1: NF-κB signals are required for LMP1-mediated
induction of 4-1BB. Quantitative PCR of 4-1BB mRNA in Jurkat cells after
transfection of wt-LMP1 (pSV40-LMP1) and co-transfection of pIκBα-DN or
treatment with the IKKβ inhibitor ACHP (2-Amino-6-(2-(cyclopropylmethoxy)-
6-hydroxyphenyl)-4-(4-piperidinyl)-3-pyridine-carboni-trile) solved in
DMSO. ACHP (10 μM) was added 24 h after transfection for 24 h. Relative
copy numbers were determined by normalizing 4-1BB transcripts to those of
ACTB. Mean values +/− SE were compared using a t-test (n = 4). * indicates
P < 0.05; **, P < 0.01.
Additional file 2: NF-κB signals are required for maintaining
expression of 4-1BB in lymphoblastoid cells. Quantitative PCR of 4-1BB
transcripts normalized to ACTB in LCL-B upon ACHP-and SP600125-treatment
for 48 h. The means of three independent experiments +/− SE were
normalized to solvent-treated cells and compared using a paired t-test.
** indicates P < 0.01.
Additional file 3: Enirchment of transfected cells by magnetic
separation. FACS analysis of transfected Jurkat cells before and after
magnetic separation. Jurkat cells were transfected with pMACS-LNGFR,
wt-LMP1 (pSV-LMP1) and shFascin5, shFascin4 or shNonsense (shNon).
Cells were stained for LNGFR expression and subjected to magnetic
separation. The percentage of LNGFR-positive cells (mean values +/− SE)
is shown (at least 4 experiments).Abbreviations
ACHP: 2-Amino-6-(2-(cyclopropylmethoxy)-6-hydroxyphenyl)-4-(4-piperidinyl)-
3-pyridine-carbonitrile; ACTB: β-actin; BL: Burkitt lymphoma; CTAR: C-terminal
activation region; DTT: Dithiothreitol; EBV: Epstein-Barr virus; FAM: 6-
carboxyfluorescein; FCS: fetal calf serum; FSC: Forward scatter; FSCN1: Fascin;
HHV-4: Human herpesvirus 4; HL: Hodgkin lymphoma; HTLV-1: Human
T-lymphotropic virus type 1; IKK: IκB kinase; LCL: Lymphoblastoid cell line;
JNK: c-Jun N-terminal kinase; LMP1: Latent membrane protein 1;
LNGFR: Low-affinity nerve growth factor receptor; NGF-R: Nerve growth
factor receptor; NIK: NF-κB inducing kinase; NF-κB: Nuclear factor kappa B;
NPC: Nasopharyngeal carcinoma; PEL: Primary effusion lymphoma;
SDS: Sodium dodecyl sulfate; SSC: Side scatter; STAT: Signal transducer and
activator of transcription; TAMRA: Tetramethylrhodamine; TNFR: Tumor
necrosis factor receptor; TRADD: TNF-receptor associated death domain;
TRAF: Tumor necrosis factor receptor-associated factor.
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